Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
Information Services Applications, Penn Medicine, University of Pennsylvania, Philadelphia, PA.
JCO Clin Cancer Inform. 2023 Aug;7:e2300024. doi: 10.1200/CCI.23.00024.
To develop an electronic health record (EHR)-based clinical decision support (CDS) tool to promote guideline-recommended cancer risk management among patients with Lynch syndrome (LS), an inherited cancer syndrome that confers an increased risk of colorectal and other cancer types.
We conducted a cross-sectional study to determine the baseline prevalence and predictors of guideline-recommended colonic surveillance and annual genetics program visits among patients with LS. Multivariable log-binomial regressions estimated prevalence ratios (PRs) of cancer risk management adherence by baseline sociodemographic and clinical characteristics. These analyses provided rationale for the development of an EHR-based CDS tool to support patients and clinicians with LS-related endoscopic surveillance and annual genetics program visits. The CDS leverages an EHR platform linking discrete genetic data to LS Genomic Indicators, in turn driving downstream clinician- and patient-facing CDS.
Among 323 patients with LS, cross-sectional adherence to colonic surveillance and annual genetics program visits was 69.3% and 55.4%, respectively. Patients with recent electronic patient portal use were more likely to be adherent to colonic surveillance (PR, 1.67; 95% CI, 1.11 to 2.52). Patients more recently diagnosed with LS were more likely to be adherent to annual genetics program visits (PR, 0.58; 95% CI, 0.44 to 0.76 for 2-4 years; PR, 0.62; 95% CI, 0.51 to 0.75 for ≥4 compared with <2 years). Our EHR-based CDS tool is now active for 421 patients with LS throughout our health system.
We have successfully developed an EHR-based CDS tool to promote guideline-recommended cancer risk management among patients with LS.
开发一种基于电子健康记录(EHR)的临床决策支持(CDS)工具,以促进林奇综合征(LS)患者遵循指南推荐的癌症风险管理,LS 是一种遗传性癌症综合征,会增加结直肠癌和其他癌症类型的风险。
我们进行了一项横断面研究,以确定 LS 患者遵循指南推荐的结肠监测和年度遗传计划就诊的基线患病率和预测因素。多变量对数二项式回归估计了癌症管理依从性的患病率比(PR),根据基线社会人口统计学和临床特征进行分析。这些分析为开发基于 EHR 的 CDS 工具提供了依据,以支持 LS 相关内镜监测和年度遗传计划就诊的患者和临床医生。CDS 利用 EHR 平台将离散的遗传数据与 LS 基因组指标联系起来,进而推动下游面向临床医生和患者的 CDS。
在 323 名 LS 患者中,结肠监测和年度遗传计划就诊的横断面依从率分别为 69.3%和 55.4%。最近使用电子患者门户的患者更有可能遵守结肠监测(PR,1.67;95%CI,1.11 至 2.52)。最近被诊断为 LS 的患者更有可能遵守年度遗传计划就诊(PR,0.58;95%CI,2-4 年为 0.44 至 0.76;PR,≥4 年与<2 年相比为 0.62;95%CI,0.51 至 0.75)。我们的基于 EHR 的 CDS 工具现在在我们的整个医疗系统中为 421 名 LS 患者启用。
我们已成功开发了一种基于 EHR 的 CDS 工具,以促进 LS 患者遵循指南推荐的癌症风险管理。